此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

青少年脊柱关节炎的生物消减和捕获儿童的结果和耀斑频率 (BACK-OFF JSpA)

2026年9月22日 更新者:Children's Hospital of Philadelphia

青少年脊柱关节炎 (BACK-OFF JSpA) 的生物消减和捕获儿童的结果和耀斑频率

This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 31 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.

研究概览

详细说明

This project is a prospective, 12-month (+/- 1 month) pragmatic randomized trial embedded within routine clinical care. Children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a TNFi for 6 months or longer will be eligible for enrollment. Children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of TNFi (arm 2), or stopping TNFi (arm 3). The recommended visit frequency is every 3 months (+/- 1 month) through the study endpoint at 12 months (+/- 1 month). After subjects have followed their treatment assignment for 12 months (+/- 1 month), those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. All participants will be monitored for 24 additional months for long-term outcomes after the intervention period.

研究类型

介入性

注册 (实际的)

164

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5G 1E8
        • The Hospital for Sick Children
    • Alabama
      • Birmingham、Alabama、美国、35294
        • University of Alabama at Birmingham
    • Arizona
      • Phoenix、Arizona、美国、85006
        • Phoenix Children's
    • California
      • Los Angeles、California、美国、90027
        • Children's Hospital Los Angeles
      • Palo Alto、California、美国、94304
        • Stanford University
    • Colorado
      • Aurora、Colorado、美国、80045
        • Children's Hospital of Colorado
    • Delaware
      • Wilmington、Delaware、美国、19803
        • Nemours Children's Hospital
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • Children's National Health System
    • Florida
      • Orlando、Florida、美国、32827
        • Nemours Children's Health
    • Georgia
      • Atlanta、Georgia、美国、30329
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago、Illinois、美国、60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Riley Hospital for Children at IU Health
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa Stead Family Children's Hospital
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • University of Minnesota Masonic Children's Hospital
    • Missouri
      • Kansas City、Missouri、美国、64108
        • Children's Mercy Hospital
      • St Louis、Missouri、美国、63110
        • St. Louis Children's Hospital
    • New York
      • New York、New York、美国、10021
        • Hospital for Special Surgery
      • Queens、New York、美国、11040
        • Cohen Children's Medical Center
    • Ohio
      • Akron、Ohio、美国、44302
        • Akron Children's Hospital
      • Cincinnati、Ohio、美国、45229
        • Cincinnati Children's Hospital Medical Center
      • Columbus、Ohio、美国、43205
        • Nationwide Children's Hospital
    • Oregon
      • Portland、Oregon、美国、97227
        • Randall Children's Hospital at Legacy Emanuel
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • The Children's Hospital of Philadelphia
      • Pittsburgh、Pennsylvania、美国、15224
        • UPMC Children's Hospital of Pittsburgh
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • Vanderbilt Children's Hospital
    • Texas
      • Dallas、Texas、美国、75390
        • UT Southwestern Medical Center
      • Houston、Texas、美国、77030
        • Texas Children's Hospital - Baylor College of Medicine
    • Utah
      • Salt Lake City、Utah、美国、84113
        • Primary Children's Hospital
    • Washington
      • Seattle、Washington、美国、98105
        • Seattle Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

8年 至 21年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Males or females age 8 to 21 years

  2. Juvenile SpA diagnosis:

    • Symptom onset before their 16th birthday:

    o International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis enthesitis-related arthritis subtype

    OR;

    • Symptom onset before their 18th birthday:

    o Pediatric Rheumatology International Trials Organization (PRINTO) revision of the ILAR criteria enthesitis spondylitis-related JIA

    • Peripheral arthritis and enthesitis, or
    • Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on imaging, or
    • Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative.
    • If peripheral arthritis is present, it should persist for at least 6 weeks.
  3. Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, or TNFi biosimilar) at standard doses

  4. Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician

  5. English speaking or Spanish speaking

  6. Subject's treating physician recommended that he/she is a good candidate to participate in the study, which may include a modified therapy

  7. Interested and willing to de-escalate TNFi therapy

Exclusion Criteria:

1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:TNFi Standard Therapy

Continue fixed standard treatment (i.e., no change from current therapy)

Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.

实验性的:TNFi fixed longer dosing intervals

Fixed longer dosing intervals of TNFi (i.e., increased time between doses)

Participants randomly assigned to this arm will increase the time between TNFi medication doses.

  • Adalimumab- from every 2 to 3 weeks
  • Certolizumab- from every 2 to 4 weeks
  • Etanercept- from every 1 to 2 weeks
  • Golimumab- from every 4 to 6 weeks
  • Infliximab- from baseline to baseline + 2 weeks
实验性的:TNFi Therapy Withdrawal

Stop TNFi treatment

Participants randomly assigned to this arm will stop TNFi medication.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Juvenile Spondyloarthritis (JSpA) flare
大体时间:12 months

JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in function is defined as ≥3 unit change in the PROMIS mobility or upper extremity T-scores. The Patient-Reported Outcomes Measurement Information System (PROMIS) short forms include 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation of 10. Active joint count is defined as the number of joints with swelling or, in the absence of swelling, limitation of motion accompanied by pain or warmth as per the physician examination.

12 months

次要结果测量

结果测量
措施说明
大体时间
Pain interference (as measured by the PROMIS short form)
大体时间:12 months

Pain interference (as measured by the PROMIS short form) of children with spondyloarthritis in the three treatment arms. The PROMIS short form is a validated questionnaire that measures the self-reported consequences of pain on relevant aspects of a person's life.The PROMIS short form includes 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation equal to 10.

12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年11月11日

初级完成 (实际的)

2026年6月1日

研究完成 (实际的)

2026年6月1日

研究注册日期

首次提交

2021年5月14日

首先提交符合 QC 标准的

2021年5月14日

首次发布 (实际的)

2021年5月18日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 21-018442
  • : GRT-00001036 (其他赠款/资助编号:PCORI)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅